StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > A short math lesson...

<< Previous

Bullboard Posts

Next >>

Comment by gojotv!on Apr 06, 2021 7:48pm

97 Views

Post# 32946614

RE:RE:RE:A short math lesson...

The 70% profit margin they've calculated looks good to me.
If a new cost factor is going to be 30% of projected revenues, I'm great with that. But hey, thanks for ba-... uh, I mean, posting!

johnny007 wrote: I explained the dissappointment in an earlier post.

But again, the huge problem is that nobody wanted to deal with Aristotle
_AND_ that they now also added a huge new cost factor just to
try to sell Aristotle.

This is a big game changer.
It is like going from creating [, producing] and selling cakes
to bakeries to become a state wide bakery chain
with unforseen cost factors.

And now ask yourself, do you really trust company
to manage this new cost position well?